BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15880395)

  • 1. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin and axonal Na+ channel function in vivo.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
    Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
    Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
    Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
    Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
    Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
    Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
    Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
    Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
    Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
    Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
    Tofthagen C; McAllister RD; McMillan SC
    Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
    Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
    Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss.
    Jamieson SM; Liu J; Connor B; McKeage MJ
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):391-9. PubMed ID: 15887017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on oxaliplatin-induced peripheral nerve damage.
    Argyriou AA; Polychronopoulos P; Iconomou G; Chroni E; Kalofonos HP
    Cancer Treat Rev; 2008 Jun; 34(4):368-77. PubMed ID: 18281158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.